The Russian subsidiary of British pharmaceutical giant AstraZeneca has announced that it will conduct clinical trials in combination with a vaccine for the new coronavirus that is being developed with Oxford University and a Russian vaccine.
The clinical trial is proposed by the Russian side, and AstraZeneca may be able to expect a higher preventive effect.
On the 11th, the Russian subsidiary of British pharmaceutical giant AstraZeneca will conduct a clinical trial to investigate the effect of using the new coronavirus vaccine under development with Oxford University in combination with the Russian domestic vaccine "Sputnik V". Announced to do.
Both vaccines are given twice, and clinical trials will be conducted in combination and will start in December.
According to AstraZeneca, "combining different vaccines can be an important step in strengthening the immune response and producing a higher preventive effect."
In this clinical trial, a government fund involved in vaccine development in Russia, the Russian direct investment fund, etc. proposed to the AstraZeneca side, and the Russian direct investment fund said, "A new chapter of cooperation on vaccines It has begun, "he emphasizes its significance.
It seems that Russia also wants to promote the effectiveness of Russian vaccines by collaborating with the British side in vaccine development, and to give momentum to sales to each country.